NEWARK, Calif., Dec. 15, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage
biopharmaceutical company, today announced the closing of its
previously announced underwritten public offering of 5,476,189
shares of its common stock, including 714,285 shares sold pursuant
to the underwriters' exercise in full of their "green shoe" option
to purchase additional shares, at a price to the public of
$21.00 per share. Aggregate gross
proceeds to Protagonist from the offering were approximately
$115.0 million, before deducting
underwriting discounts and commissions and offering
expenses.
J.P. Morgan Securities LLC, SVB Leerink LLC, Piper Sandler
& Co. and BMO Capital Markets Corp. are acting as joint
book-running managers for the offering.
A shelf registration statement relating to the offered shares of
common stock was filed with the Securities and Exchange Commission
(SEC) on December 10, 2020. A final
prospectus supplement and accompanying prospectus relating to the
offering have been filed with the SEC and is available on the SEC's
website, located at www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus related to
the offering may be obtained, when available, from J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY
11717, by telephone at (866) 803-9204 or by email at
prospectus-eq_fi@jpmchase.com; from SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at
(800) 808-7525, ext. 6132 or by email at syndicate@svbleerink.com;
from Piper Sandler & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, by
telephone at (800) 747-3924 or by email at prospectus@psc.com; or
from BMO Capital Markets Corp., Attention: Equity Syndicate
Department, 3 Times Square, 25th Floor, New York, NY 10036, by telephone at (800)
414-3627 or by email at bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-inc-announces-closing-of-115-million-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301193424.html
SOURCE Protagonist Therapeutics, Inc.